EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of fenfluramine and sigma‐1‐dependent pharmacological and genetic modulation in a mouse kindling model

Eva-Lotta von Rüden iD, Verena Buchecker iD, Amelie Wagner iD, Victoria M Stocker iD, Liga Zvejniece iD, Heidrun Potschka iD

Epilepsia · 2026

DOI: 10.1002/epi.70270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Eva-Lotta von Rüden und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany. Hauptthemen laut MEDLINE: Kindling, Neurologic, Receptors, sigma, Seizures, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Cooperation in Science and Technology (COST Association), SIGMA-1_EUROPE action, European Cooperation in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Sigma‐1 is a chaperone protein that serves as a key homeostatic regulator, implicated in neuronal excitability and seizure control. Positive allosteric modulators offer a use‐dependent means to enhance Sigma‐1 activity, potentially with favorable tolerability compared to direct agonists. This study examined the role of sigma‐1 in ictogenesis, seizure spread, and termination, and evaluated whether sigma‐1 targeting could modify progression in the amygdala kindling model.

Methods

Using the mouse amygdala kindling paradigm, we assessed the effects of subchronic administration of the sigma‐1 positive allosteric modulator E1R and of the antiseizure medication fenfluramine on seizure thresholds, severity, duration, and progression of kindling. Tolerability, behavioral outcomes, and potential disease‐modifying effects were evaluated. Additional experiments investigated the influence of sigma‐1 antagonism (NE‐100) and genetic sigma‐1 deficiency on E1R efficacy and seizure development.

Results

E1R delayed kindling acquisition, increased seizure thresholds in both naïve and kindled animals, and reduced seizure duration without evidence of tolerance or significant adverse effects. Subchronic E1R exposure slowed or prevented progression to generalized seizures, although effects did not persist after drug withdrawal. Sigma‐1 deficiency prolonged seizure duration, supporting a role in the termination of endogenous seizures. High‐dose NE‐100 partially antagonized E1R effects, whereas genetic deficiency did not, possibly due to compensatory mechanisms. Fenfluramine did not affect kindling progression in this model. Significance Positive allosteric modulation of sigma‐1 attenuates ictogenesis and seizure severity and appears to contribute to endogenous seizure‐termination mechanisms. Although E1R influences seizure generation in response to repeated stimulation, it does not produce sustained disease‐modifying effects after discontinuation. These findings support a functional role of sigma‐1 positive allosteric modulators as promising candidates for seizure management in the model used. The absence of persistent effects after withdrawal argues against disease modification under the current conditions and warrants further investigation in chronic epilepsy models evaluating long‐term therapeutic, disease‐modifying, or preventive potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kindling, NeurologicReceptors, sigmaSeizuresAnticonvulsantsFenfluramineAnimalsMiceMaleDisease Models, AnimalSigma-1 ReceptorAmygdalaMice, Inbred C57BLMice, KnockoutAnisoles

Stichwörter der Autor:innen

E1RNE‐100antiseizure medicationsigma‐1 knockouttemporal lobe epilepsy

Substanzen

Receptors, sigmaAnticonvulsantsSigma-1 ReceptorFenfluramineAnisoles

Autor:innen und Institutionen

  • Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany.
  • Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia.

ORCID-Profile: Eva-Lotta von Rüden, Verena Buchecker, Amelie Wagner, Victoria M Stocker, Liga Zvejniece, Heidrun Potschka

Förderung

  • Deutsche Forschungsgemeinschaft
  • European Cooperation in Science and Technology (COST Association), SIGMA-1_EUROPE action
  • European Cooperation in Science and Technology

Zitieren

APA

von Rüden, E. L., Buchecker, V., Wagner, A., Stocker, V. M., Zvejniece, L., & Potschka, H. (2026). Effects of fenfluramine and sigma‐1‐dependent pharmacological and genetic modulation in a mouse kindling model. Epilepsia. https://doi.org/10.1002/epi.70270

Vancouver

von Rüden EL, Buchecker V, Wagner A, Stocker VM, Zvejniece L, Potschka H. Effects of fenfluramine and sigma‐1‐dependent pharmacological and genetic modulation in a mouse kindling model. Epilepsia. 2026. doi:10.1002/epi.70270

BibTeX
@article{vonRden2026,
  author = {von Rüden, Eva-Lotta and Buchecker, Verena and Wagner, Amelie and Stocker, Victoria M and Zvejniece, Liga and Potschka, Heidrun},
  title = {Effects of fenfluramine and sigma‐1‐dependent pharmacological and genetic modulation in a mouse kindling model},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1002/epi.70270}
}
Kostenlos starten →